Research shows that Vδ1 and Vδ3 γδ T cells that express PD-1 and display potent cytotoxic functions are key immune responders in HLA-class-I-negative colon cancers subjected to immune checkpoint blockade therapy.
This is a preview of subscription content, log in via an institution to check access.
References
Ijsselsteijn, M. E. et al. Br. J. Cancer 120, 815–818 (2019).
de Vries, N. L. et al. Nature https://doi.org/10.1038/s41586-022-05593-1 (2023).
Nishino, M. et al. Nat. Rev. Clin. Oncol. 14, 655–668 (2017).
Silva-Santos, B., Mensurado, S. & Coffelt, S. B. Nat. Rev. Cancer 19, 392–404 (2019).
Mikulak, J. et al. JCI Insight 4, 125884 (2019).
Wu, Y. et al. Sci. Transl. Med. 11, eaax9364 (2019).
Wu, Y. et al. Nat. Cancer 3, 696–709 (2022).
de Vries, N. L. et al. Gut 69, 691–703 (2020).
Hoeres, T. et al. Oncoimmunology 8, 1550618 (2019).
Rossi, C. et al. Oncoimmunology 8, 1554175 (2019).
Nada, M. H. et al. Oncoimmunology 10, 1989789 (2021).
Almeida, A. R. et al. Clin. Cancer Res. 22, 5795–5804 (2016).
Acknowledgements
We acknowledge funding from Fundação para a Ciência e Tecnologia of Portugal’s Ministério da Ciência, Tecnologia e Ensino Superior (PTDC/MED-ONC/6829/2020 to B.S.-S. and 2021.01953.CEECIND to S.M.).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors receive funding support from Takeda Development Center Americas, Inc. (Lexington, MA, USA).
Rights and permissions
About this article
Cite this article
Silva-Santos, B., Mensurado, S. γδ T cells maintain sensitivity to immunotherapy in MHC-I-deficient tumors. Nat Immunol 24, 387–388 (2023). https://doi.org/10.1038/s41590-023-01429-w
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41590-023-01429-w
- Springer Nature America, Inc.